The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is a novel multiple receptor tyrosine kinase inhibitor used for hepatocellular carcinoma (HCC) treatment. Although its main function is to suppress VEGFR and FGFR pathway, its immunomodulatory activity in HCC is not elucidated. Thus, this study aimed to investigate the immunom...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jie, Fang, Peiqi, Wang, Chong, Gu, Meixiu, Pan, Baishen, Guo, Wei, Yang, Xinrong, Wang, Beili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607247/
https://www.ncbi.nlm.nih.gov/pubmed/34605616
http://dx.doi.org/10.1002/cam4.4312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607247/
https://www.ncbi.nlm.nih.gov/pubmed/34605616
http://dx.doi.org/10.1002/cam4.4312

Ejemplares similares